轩竹生物上市首日涨幅近127%；强生前三季度营收约696亿美元｜医药早参

Group 1 - XuanZhu Biotech officially listed on the Hong Kong Stock Exchange on October 15, raising a total of HKD 780 million by issuing 67.33 million shares at an offering price of HKD 11.60 per share [1] - On its first trading day, XuanZhu Biotech's stock price surged to HKD 26.30 per share, marking a daily increase of 126.72% [1] - The strong market reception indicates investor confidence in high-quality innovative pharmaceutical companies, with XuanZhu Biotech poised to benefit from ongoing industry trends through accelerated R&D funded by the raised capital [1] Group 2 - GlaxoSmithKline's recombinant shingles vaccine, Shingrix, received approval for a new indication from the National Medical Products Administration in China [2] - The new indication allows the vaccine to be used for adults aged 18 and older who are at increased risk of shingles due to known diseases or treatments that cause immunodeficiency or immunosuppression [2] - This approval addresses the vaccine needs of high-risk groups and further solidifies GlaxoSmithKline's competitive position in the shingles vaccine market [2] Group 3 - Johnson & Johnson reported third-quarter revenue of USD 23.993 billion, reflecting a year-over-year growth of 6.8% [3] - For the first nine months of the year, Johnson & Johnson's total revenue reached approximately USD 69.6 billion, driven by growth in both its innovative pharmaceuticals and medical technology segments, which generated revenues of USD 44.638 billion and USD 23.669 billion, respectively [3] - The revenue growth demonstrates the company's operational resilience, supported by strong performance in both business segments [3]